Several other brokerages have also issued reports on VRTX. Evercore ISI started coverage on shares of Homology Medicines in a research note on Thursday, April 11th. They issued an outperform rating and a $29.00 price target on the stock. Goldman Sachs Group raised shares of Lenovo Group from a neutral rating to a buy rating in a research report on Thursday, May 23rd. They noted that the move was a valuation call. Needham & Company LLC reissued a buy rating and issued a $10.00 price objective (down previously from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. Svb Leerink reissued an outperform rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, March 19th. Finally, William Blair reissued a market perform rating on shares of aTyr Pharma in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seventeen have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $204.36.
Shares of NASDAQ:VRTX opened at $176.01 on Tuesday. The firm’s fifty day moving average price is $175.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals has a 12-month low of $151.80 and a 12-month high of $195.81. The firm has a market cap of $45.78 billion, a P/E ratio of 55.34, a P/E/G ratio of 2.59 and a beta of 1.43.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.49. The firm had revenue of $857.00 million for the quarter, compared to analysts’ expectations of $853.00 million. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The business’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same period last year, the firm earned $0.76 earnings per share. Analysts expect that Vertex Pharmaceuticals will post 3.06 EPS for the current year.
In other news, EVP Stuart A. Arbuckle sold 5,624 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $181.75, for a total value of $1,022,162.00. Following the transaction, the executive vice president now directly owns 36,272 shares of the company’s stock, valued at $6,592,436. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey M. Leiden sold 10,480 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $175.08, for a total transaction of $1,834,838.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 227,804 shares of company stock worth $39,955,223. Company insiders own 0.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. PFS Investments Inc. raised its position in Vertex Pharmaceuticals by 208.2% in the second quarter. PFS Investments Inc. now owns 6,912 shares of the pharmaceutical company’s stock worth $1,233,000 after purchasing an additional 4,669 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 64.0% during the second quarter. Valeo Financial Advisors LLC now owns 1,069 shares of the pharmaceutical company’s stock worth $196,000 after purchasing an additional 417 shares in the last quarter. Pennsylvania Trust Co boosted its position in shares of Vertex Pharmaceuticals by 39.6% during the second quarter. Pennsylvania Trust Co now owns 5,841 shares of the pharmaceutical company’s stock worth $1,071,000 after purchasing an additional 1,657 shares in the last quarter. New England Research & Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 88.0% during the second quarter. New England Research & Management Inc. now owns 2,350 shares of the pharmaceutical company’s stock worth $431,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its position in shares of Vertex Pharmaceuticals by 2.6% during the second quarter. Retirement Systems of Alabama now owns 154,381 shares of the pharmaceutical company’s stock worth $28,310,000 after purchasing an additional 3,945 shares in the last quarter. 94.94% of the stock is currently owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Story: Outperform Rating
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.